Silexion Therapeutics Corp
SLXN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002022416
No open-market purchases or sales by Silexion Therapeutics Corp insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $42.5K in total; no superinvestor holds it.
Other share classesSLXNW
Q2 2026 vs. Q1 2026
How the institutions holding Silexion Therapeutics Corp changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 7 | 6 | −1 |
| Shares | 36.5K | 17.1K | −19.4K (−53.2%) |
| Value | $46.7K | $42.5K | −$4.24K (−9.1%) |
New holders (2)
Institutions that held Silexion Therapeutics Corp at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HRT Financial LP | 15,239 | $38.0K | 0.00% |
| Royal Bank of Canada | 76 | $0 | 0.00% |
Sold out (3)
Institutions that held Silexion Therapeutics Corp at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Citadel Advisors LLC | 20,926 | $26.8K |
| Two Sigma Securities, LLC | 11,657 | $14.9K |
| Jones Financial Companies LLLP | 26 | $32 |